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Setting. Multidisciplinary tertiary care pain center within the Montreal University Health Center.
Subjects. Patients who had had at least one visit at least one year prior to the invitation.
Methods. We used four questionnaires: demographic questionnaire, the Drug Attitude Inventory Modified (DAI-M), the Opioid Risk Tool (ORT), and the Screening Tool for Addiction Risk (STAR). All questionnaires were administered in their validated French version.
Results. Three hundred seventy patients completed questionnaires. The response rate was 79.26%. Of those who responded, 61.62% women and 38.38% men, the mean age was 57 years. The patients had been treated with LtOT for an average of 6.31 years, and the median dose per day in morphine equivalents was 48.21 mg. The DAI-M showed that 32.16% had a positive attitude toward opioids, 39.73% had a negative attitude, and 22.16% had a neutral attitude. The ORT questionnaire demonstrated that 86.2% of the patients were at low risk of abuse/misuse, 13.2% were at moderate risk, and only 0.54% were at high risk. The STAR questionnaire showed that 4.2% had a low risk of abuse/misuse.
Conclusions. Despite public opinion, patients treated with LtOT for CNCP and followed in a tertiary care pain center are at low risk for opioid misuse/abuse. We need to refine the way of prescribing opioids, should be selective with our patients, and should relive their pain adequately.
Introduction
Tremendous progress has been made in the study and treatment of pain in the past two decades. Efforts have been undertaken to make pain assessment and treatment a priority of medical care and to use all of the weapons in our arsenal [1] to bring relief to the millions of people who suffer with chronic pain. However, this progress has been somewhat tempered by the souring of the regulatory climate and the growth of prescription drug abuse.
Despite these setbacks, the use of long-term opioid therapy (LtOT) to treat chronic noncancer pain is growing, based in part on evidence from clinical trials and a growing consensus among pain specialists [2] . The appropriate use of these drugs requires a commitment to performing and documenting a comprehensive assessment repeatedly over time, skill in the prescription of opioids, and knowledge of the issues related to misuse/ abuse. Physicians specialized in pain management have acquired the highly specialized knowledge and skills in opioid prescription, and they routinely complete comprehensive exams and document their findings. What is needed to round out these three elements, to aid in the appropriate use of opioids, is knowledge of the actual risk for misuse/abuse faced by patients followed in accredited pain centers.
In order to acquire this information, a descriptive study to evaluate both the attitudes of patients toward taking opioids and their risk of misuse/abuse based on the currently used questionnaires was created. The purpose of this article is to shed light on the probability of opioid misuse/abuse among patients on LtOT. The intent of this article is to provide treating physicians with the confidence to deliver the most appropriate care for patients living with chronic pain.
Methods
This is a prospective, descriptive epidemiological study conducted in a multidisciplinary tertiary care pain center. After obtaining ethics approval (Montreal University Hospital Center no 2011-3613, CE 09.257-BSP; Nagano Identifier: CE 09.257), all patients who had been followed at the center for at least one year were sent an invitation through the mail; if they responded by returning a signed consent form, a trained research nurse contacted them over the phone. Four questionnaires were used: a demographic questionnaire, the Drug Attitude Inventory (DAI), the Opioid Risk Tool (ORT), and the Screening Tool for Addiction Risk (STAR). All questionnaires were administered in their validated French version.
Definitions
Opioid use disorder: Although some clinicians in the pain community believe that the DSM criteria for OUD are not fully applicable to pain patients taking prescribed opioids as many of the described behaviors are very common in patients not abusing their opioids, the authors chose to rely on these definitions [3] . When constructing the study, the DSM-IV-TR definitions were used [4] . However, when evaluating the data, the new criteria found in the DSM-5 were incorporated [5] . This iteration of the DSM contains a new streamlined section under the title "Opioid-Related Disorders" and is composed of five subsections. Here, diagnostic criteria are specifically and clearly set out for the practitioner. These criteria are well reflected in the recommended screening questionnaires that were used in this study.
Long-term opioid therapy (LtOT): In this study, LtOT is defined as receiving opioids for chronic noncancer pain treatment for more than one year.
Attitude: Is defined as a disposition or tendency to respond positively or negatively toward a certain idea, object, person, or situation [6] . Attitudes encompass or are closely related to opinions and beliefs and are based upon experience [7] .
Questionnaires
Four questionnaires were used: 1) a demographic, intensity of pain, and follow-up information questionnaire, 2) the DAI questionnaire, 3) the ORT questionnaire, and 4) the STAR questionnaire.
The demographic information questionnaire included: age, sex, level of education, job status, and type of pain. Pain and follow-up status included the length of time the patient had suffered from chronic pain, the length of time they had been taking opioids, and the length of time they had been followed in the chronic pain clinic.
Pain intensity information collected included: 1) the intensity of pain at the time of the questionnaire, 2) the average pain over the last seven days, and 3) the worst pain in the last seven days.
Drug Attitude Inventory Questionnaire
The Drug Attitude Inventory questionnaire (DAI-10), the short version of the DAI-30, was used [8] . The aim of this questionnaire was to gain some understanding of what people think about medications and what experiences people have when using them. The questionnaire was originally designed by Dr. Awad to identify the subjective responses of patients with schizophrenia taking neuroleptic drugs and their attitude toward disease and treatment, and it showed good internal coherence and a high validity in the original study [9] , as well as one based on a study of 150 patients [7] . This is the first time that the questionnaire has been used in a pain population. As such it has not been validated for this Vargas-Schaffer and Cogan particular population; however, it was chosen as there are several similarities between patients with chronic pain and patients with schizophrenia, specifically the chronic use of medication, the social stigma attached to these medications, and the need to take these drugs in order to be functional. The questionnaire was adapted for patients with CNCP after approval from Dr. Awad, who provided an acceptance in principle for a new study population. The modifications made to the original questionnaire were small wording changes to reflect the change in population. In question 7, the words "feel pain" instead of "feel ill" were used. In question 10, the words "having crises of pain" instead of "having a breakdown" were used. This revised questionnaire was referred to as the DAI modified (DAI-M).
Scoring of the DAI-10
As per De las Cuevas [7] , the DAI-10 questionnaire is a self-report scale that has 10 items that the patient scores as true or false. For six of the items (1, 3, 4, and 8-10), a true response is considered positive, whereas for the other four items (2, 5, 7, and 11) a false response is considered positive. A positive answer was scored as þ1 and a negative answer as -1. The final score was the sum of the 10 scores. Positive and negative total scores indicated positive and negative attitudes toward psychiatric medication, respectively. The validated French version was used and scored patient's overall attitudes as positive, negative, or neutral. Attitudes were described as neutral when patients had equal numbers of positive and negative answers.
In addition, five questions intended to assess the presence of fear of taking medication, the potential sense of stigma related to the use of opioids, and feelings of dependence that may result when patients are trying to maintain low levels of pain; high levels of functionality were added. The impetus for the creation of these questions arose from clinical experience that led us to believe that these might be issues for patients and, if accurately identified, would be amenable to intervention through education.
The Opioid Risk Tool
The Opioid Risk Tool (ORT) was created by Webster and Webster [10] , using the best known risk factors for abuse in order to aid clinicians in their office in evaluating the probability that a patient would abuse opioids during treatment. It was designed to predict the probability of patients displaying aberrant drug behavior when opioids are prescribed for chronic pain and is the recommended tool both nationally and provincially for the safe and effective use of opioids for noncancer pain. The ORT contains five questions with "yes" or "no" answers, and three of the questions have subsections. Each question has been assigned a specific weight, and that weight may differ depending on whether the patient is male or female. The ORT categorizes the population into three groups depending on their scores: low risk (0-3), moderate risk (5-7), and high risk (more than 8).
The Screening Tool for Addiction Risk Questionnaire
The Screening Tool for Addiction Risk (STAR) questionnaire is a screening tool for misuse/abuse risk consisting of 14 true or false questions, developed for use in chronic pain patients who attend a pain clinic and are undergoing long-term opioid treatment. The answers are dichotomous variables, either "yes" or "no." It has shown validity in initial testing [11] . The most significant predictor of risk of misuse/abuse is a history of treatment in a drug or alcohol treatment facility. There is also a close relationship between cigarette smoking, a feeling of smoking too much, and a history of treatment in a drug or alcohol rehabilitation facility.
Freidman [11] identified that factor analysis using questions related to tobacco abuse and prior treatment for drug and alcohol abuse, which distinguished between patients with misuse/abuse and pain from patients with chronic pain and long-term opioid therapy, and that history of treatment in a drug or alcohol rehabilitation facility was a significant predictor of misuse/abuse with a positive predictive value of 93%.
Results

Demographics
For this study, 2,599 invitations were sent to potential participants inviting them to participate in the 3ADC study, as per the ethics committee request. This included all patients who had had at least one visit more than one year prior to the invitation. The list was compiled using the internal registry of the clinic (Figure 1 ). Although the ethics committee request was followed, screening of the participants showed that 1,690 did not to meet the study criteria whereas 909 patients did meet the criteria. Of these, 539 (59%) patients declined to participate (as they were recruited to another study) and 370 (41%) patients agreed to participate. The following formula used by Statistics Canada was applied to calculate the response rate. Response Rate ¼ Completes dived by (Completes) þ (Completes divided by (Completes þ Not Qualified) multiplied by (Not contacted þ Refused). There was a 79.26% response rate for this study.
Of the 370 patients who participated, 61.62% were women and 38.38% were men. The mean age was 57 years (range ¼ 26-91 years), and 75.4% were under 65 years of age. Fifty-three point five percent (53.52%) had a college or university education, and 69.19% were retired or on workman's compensation (Table 1) .
Addiction and Misuse/Abuse in Long-term Opioid Therapy
Types of Pain, Pain Scores, and Intensity
The four main types of pain for which patients had consulted were spinal pain (49.19%), musculoskeletal pain (10.0%), neuropathic pain (9.73%), and fibromyalgia pain (7.03%). They represented 75.95% of different types of pain (Table 2) .
Mean pain intensity (NRS 0-10) at the time of the questionnaire was 5.6 (95% CI ¼ 5.37-5.86), and average length of time, in years, of suffering from chronic pain was 10.9 years (95% CI ¼ 10.0-11.8). Mean length of time, in years, of taking opioids was (95% CI ¼ 5.8-6.3). Length of follow-up time in the pain clinic was 5.11 years (95% CI ¼ 4.70-5.53).
Opioid Use in Morphine Equivalents
The four most frequently used opioids were hydromorphone, oxycodone, fentanyl, and tramadol. Table 3 . The median dose per day of these medications was 40 mg (Q1-Q3: 15-100 mg) for hydromorphone, 48 mg (Q1-Q3: 16-96 mg) for oxycodone, 180 mg (Q1-Q3: Figure 1 Study flow chart: 2,599 invitations were sent to participate in the study. One thousand six hundred ninety patients did not meet the study criteria. Nine hundred nine patients were eligible. Five hundred thirty-nine refused to participate as they were in another study. Three hundred seventy agreed to participate and complete the study. *Opioid Rx less than 12 months; language barrier, hospitalized patients: for medical and psychiatric reasons. 90-360 mg) for fentanyl, and 25 mg (Q1-Q3: 10.93-47.65 mg) for tramadol. Methadone was the fifth most prescribed drug, and the median number of mg per day was 300 mg (Q1-Q3: 120-600 mg).
Concurrent Opioid Use
Most of the patients followed at the clinic (65.37%) were taking only one opioid, and the median mg amount was 48.21 mg per day. One hundred and ten patients (30.72%) were taking two opioids, with a median mg amount of 150.50 mg per day. Only 14 (3.9%) patients were taking three opioids concurrently, for a median mg amount of 355.0 mg per day (Table 4) .
Cannabis
Seven patients were taking synthetic cannabis as a sole treatment for pain. There are no morphine equivalents available for conversion of this drug. Twenty-seven patients were taking synthetic cannabis and another opioid concurrently.
The Drug Attitude Inventory Modified Version
The DAI-M showed that 119 patients (32.16%) had a positive attitude toward taking medications for pain and 147 patients (39.73%) had a negative attitude toward taking medications. Eighty-two patients (22.16%) had a neutral attitude toward taking medications. There were incomplete answers for 22 patients (5.95%) ( Table 5 ).
Questions Regarding Feelings of Dependence and Stigma
The number of patients who felt dependent on medication in order to feel functional and to relieve pain was 64.32%, while the number of patients who had a fear of taking opioids but took them anyway was 40.27%. Only 5.41% of patients felt that there was a stigma attached to taking opioids (Table 6 ). Table 7 (left-hand column) shows the results for each of the five questions and subquestions in the ORT.
Opioid Risk Tool
The prescribed algorhythm was used to calculate the risk of abuse for the population where 0 to 3 was low risk: "unlikely to abuse opioids"; 4 to 7 was moderate risk: "as likely will as wont abuse opioids"; and high risk: "likely to abuse opioids." Most patients, 86.2%, scored as being at very low risk of misuse/abuse, 13.2% scored as being at moderate risk of misuse/abuse, and 0.54% scored as being at risk of misuse/abuse ( Figure 2 ).
Screening Tool for Risk Addiction: STAR Questionnaire
The results of the individual questions from the study population are presented in Table 8 . When the three items most predictive of the risk of misuse/abuse were combined, as suggested by Friedman [11] , the number of patients with a positive answer to each of these questions was only 4.2%, compared with 95.8% for those with a negative answer for each of the questions. Table 4 presents the median number of morphine equivalents for patients taking several opioids concurrently. This demonstrates a very low risk of misuse/abuse in this study population (Figure 3) .
Statistical Correlations
The possible relationships between attitudes toward opioids and risk of misuse/abuse as per the ORT and STAR questionnaire were also evaluated. No relationship was found between these two items and pain intensity, daily morphine equivalents, level of education, job status, patient fear of opioids, length of time suffering with chronic noncancer pain, and length of treatment with opioids.
Discussion
The study results show that the most frequently used opioids were hydromorphone, oxycodone, fentanyl, and tramadol, with a median daily dose of morphine equivalents in milligrams of 40 mg, 48 mg, 180 mg, and 25 mg, respectively. Only 30.72% of patients were taking two opioids, with a median mg dose of morphine equivalents of 150.50 mg per day; very few patients were taking synthetic cannabis. These figures are much lower than those reported in the United States and by other organizations. The current Canadian guidelines for safe and effective use of opioids for chronic noncancer pain, published in 2010, recommend treating patients with dosages at or below 200 mg per day of morphine or the equivalent. The newer CDC guidelines, published in March 2016, now recommend a lower upper limit dose of 50 to 90 MEDD [12] . The Canadian guidelines also state that patients receiving higher dosages require careful reassessment Table 7 presents comparison between the current study and the original study. The risk of opioid abuse/misuse is lower in the current study. Table 6 presents the results of the dependence and stigma questions. *Questions 6 and 7 reflect that a large proportion of patients required opioids to be functional. Figure 2 The ORT for this population shows that 86.2% of patients are at low risk for abuse, 13.2% of patients are at moderate risk for abuse, and only 0.54% are at high risk for abuse.
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of their pain and of their risk for misuse, as well as frequent monitoring for evidence of decreased pain scores [2] .
Of significant importance is that both misuse/abuse questionnaires (ORT and STAR) showed that the patients attending the clinic had a very low risk for opioid abuse. Specifically, for ORT the results show that for each subsection, with the exception of one, the percentage of patients with a positive response to the item was much lower, by far, than in the original version published by Webster [10] . The only item in this study where patients scored higher was "Family history of prescription drug abuse"; the figures for this study were 15.1% whereas the original showed only 6% in this category.
Overall the ORT showed that only 11.92% of patients were at moderate or high risk of misuse/abuse while the STAR questionnaire showed that only 4.2% were at risk of misuse/abuse to opioids. This is comparable with the data presented in the Canadian Guidelines [2] , which state that the overall prevalence of opioid misuse/abuse is 3.3% in patients receiving opioids for CNCP and the prevalence of aberrant drug-related behavior is 11.5%.
After using these tools in the study population, the authors propose that a complete misuse/abuse risk evaluation of patients prior to beginning opioids should include the ORT and the three relevant questions from the STAR questionnaire. This may increase the power to detect patients who are at higher risk for misuse/abuse.
The Drug Attitude Inventory shows that 39.73% of patients had a negative attitude toward taking LtoT for the treatment of pain. These results are surprising as the original hypothesis was that larger numbers would have a negative attitude toward opioid therapy. This data can be interpreted in a positive light as meaning that most patients view taking these medications as an active and positive step toward health. It may be surmised that those who retain a negative attitude have a negative perception of their health if they are required to take any medication; that is, they have attached a negative perception of well-being to the obligation of taking medication. Figure 3 The three discriminatory questions from the STAR for this population show that 95.8% of patients were at low risk of misuse/abuse and only 4.2% of patients were at risk for misuse/abuse. The study also shows that the patients in the clinic do rely on medications to relieve pain and feel functional in the same way that a patient with asthma would require bronchodilators to relieve respiratory symptoms and feel functional. The fact that patients feel this should not immediately imply that they are addicted. Other clinicians have expressed this philosophy as well [13] .
In 2013, Kissin [14] stated that one of the main problems with prescribing opioids for long-term treatment of chronic nonmalignant pain was that information on the safety of this treatment-namely the assessment of the risk of misuse/abuse-had been neglected. Although several studies evaluating cost of opioid misuse/abuse using databases have been performed [15, 16] , few, if any, grassroots studies evaluating patients in a practice environment have been published. Therefore this study makes a significant contribution to the literature and clarifies issues related to the risk of misuse/abuse in a tertiary care setting.
Ironically the strength of this study is also its greatest limitation in that the results are specific to a tertiary care pain center population and therefore may not be easily generalizable to the primary care setting. The study evaluates patients who have an average of six years of LtOT and five years of follow-up; therefore, it is possible that patients who are at high risk of misuse/abuse have undergone a natural attrition from the pain clinic secondary to the close regular and repetitive monitoring by the clinic staff. However, the philosophy of clinic, and the clinical attitude toward treatment of patients with chronic pain, adheres closely to the NOUG guidelines [2] and therefore is reflective of many clinics across Canada as well as primary care settings with sustained regular follow-up of patients.
Recent publications and media coverage have maligned the use of opioids for the treatment of chronic pain, leaving in their wake a negative public perception. Further, publications by specialists in the domain [17] knowingly contribute to this misperception and engender widespread fear that all patients who take opioid medications for the treatment of chronic pain will ultimately run the risk of abuse. In Canada, patients being followed in a tertiary care setting are being treated with LtoT because they have a chronic disease and benefit from this well-supervised treatment. This study shows that the risk of opioid misuse/abuse is not rampant in this population. Elsewhere, much of the problem related to opioid misuse stems from the overprescription of opioids for the treatment of acute and subacute pain as well as from the misappropriation of correctly prescribed opioids by persons for whom they were not intended, either for illegitimate use or resale [18] [19] [20] . Within this context, it is important to remember the 2010 declaration made during the IASP conference in Montreal that states that access to pain management is a fundamental human right that implies the requirement of both good pain management and appropriate prescription of opioids.
Conclusion
As researchers and clinicians, we are neither opiophobic nor opiophilic, but rather supportive of an adequate pain treatment for all patients. We decry the use of terminology such as "using." A physician would never say a patient is using diuretics or antiarrhythmics because "using" is a pejorative word and connotes dependence; however, it is often stated that patients in pain are "using opioids." As espoused by Sullivan and Ballantyne [21] , there is a need to refine the manner in which opioids are prescribed by appropriately selecting patients and prescribing opioids to "control physical pain" and not to relieve the psychosocial suffering that usually accompanies chronic pain. Additionally, the authors heartily agree with the conclusion of the report published in 2014 by the Pacific Northwest Evidence-based Practice Center that more research is needed to understand long-term benefits, the risk of abuse and related outcomes, and the effectiveness of different opioid prescribing methods and risk mitigation strategies [22] .
Despite popular belief, the majority of patients in our chronic pain treatment program (and perhaps in many others) are not at high risk of misuse/abuse, nor are they taking inappropriate amounts of opioids. The authors hope that the results of this study will encourage physicians caring for patients on LtOT to continue to actively engage with their patients. Essential elements in a physician's arsenal for the optimal and effective pain management of patients on LtOT include: personalized patient education and multimodal pain medication regimens, regular follow-up and adjustment of prescriptions as well as well-honed listening and debriefing skills in a climate of empathy and respect. Patients appreciate and respond positively to physicians who take the time to listen to them and encourage them in their self-care efforts. It is hoped that these actions will result in better clinical outcomes for patients on LtOT.
